You can seek FDA approval to launch a generic drug before the expiration of ABILIFY MAINTENA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ABILIFY MAINTENA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ABILIFY MAINTENA KIT:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of AFINITOR DISPERZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the AFINITOR DISPERZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on AFINITOR DISPERZ:-

You can seek FDA approval to launch a generic drug before the expiration of BANZEL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BANZEL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BANZEL:-

You can seek FDA approval to launch a generic drug before the expiration of BELVIQ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BELVIQ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BELVIQ XR:-

You can seek FDA approval to launch a generic drug before the expiration of BETHKIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BETHKIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BETHKIS:-

You can seek FDA approval to launch a generic drug before the expiration of COMPLERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the COMPLERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on COMPLERA:-

You can seek FDA approval to launch a generic drug before the expiration of DIFICID's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DIFICID's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DIFICID:-

You can seek FDA approval to launch a generic drug before the expiration of DYMISTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the DYMISTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on DYMISTA:-

You can seek FDA approval to launch a generic drug before the expiration of ENTRESTO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ENTRESTO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ENTRESTO:-

You can seek FDA approval to launch a generic drug before the expiration of EPIDUO FORTE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPIDUO FORTE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPIDUO FORTE:-

You can seek FDA approval to launch a generic drug before the expiration of FINACEA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FINACEA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FINACEA:-

You can seek FDA approval to launch a generic drug before the expiration of GLYXAMBI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLYXAMBI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLYXAMBI:-

You can seek FDA approval to launch a generic drug before the expiration of HYSINGLA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HYSINGLA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HYSINGLA ER:-

You can seek FDA approval to launch a generic drug before the expiration of IBRANCE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the IBRANCE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on IBRANCE:-

You can seek FDA approval to launch a generic drug before the expiration of INJECTAFER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the INJECTAFER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on INJECTAFER:-

You can seek FDA approval to launch a generic drug before the expiration of JANUMET XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JANUMET XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JANUMET XR:-

You can seek FDA approval to launch a generic drug before the expiration of JENTADUETO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JENTADUETO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JENTADUETO:-

You can seek FDA approval to launch a generic drug before the expiration of JENTADUETO XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JENTADUETO XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JENTADUETO XR:-

You can seek FDA approval to launch a generic drug before the expiration of JULUCA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the JULUCA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on JULUCA:-

You can seek FDA approval to launch a generic drug before the expiration of KENGREAL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KENGREAL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KENGREAL:-

You can seek FDA approval to launch a generic drug before the expiration of KOMBIGLYZE XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the KOMBIGLYZE XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on KOMBIGLYZE XR:-

You can seek FDA approval to launch a generic drug before the expiration of MEKTOVI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MEKTOVI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MEKTOVI:-

You can seek FDA approval to launch a generic drug before the expiration of MYRBETRIQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the MYRBETRIQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on MYRBETRIQ:-

You can seek FDA approval to launch a generic drug before the expiration of NUCYNTA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NUCYNTA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NUCYNTA ER:-

You can seek FDA approval to launch a generic drug before the expiration of NYMALIZE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NYMALIZE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NYMALIZE:-

You can seek FDA approval to launch a generic drug before the expiration of ODEFSEY's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ODEFSEY's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ODEFSEY:-

You can seek FDA approval to launch a generic drug before the expiration of OMIDRIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OMIDRIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OMIDRIA:-

You can seek FDA approval to launch a generic drug before the expiration of OTEZLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OTEZLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OTEZLA:-

You can seek FDA approval to launch a generic drug before the expiration of OXAYDO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OXAYDO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OXAYDO:-

You can seek FDA approval to launch a generic drug before the expiration of OZEMPIC's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OZEMPIC's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OZEMPIC:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of POMALYST's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the POMALYST's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on POMALYST:-

You can seek FDA approval to launch a generic drug before the expiration of PRESTALIA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRESTALIA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRESTALIA:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of QTERN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the QTERN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on QTERN:-

You can seek FDA approval to launch a generic drug before the expiration of SAXENDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SAXENDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SAXENDA:-

You can seek FDA approval to launch a generic drug before the expiration of STENDRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the STENDRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on STENDRA:-

You can seek FDA approval to launch a generic drug before the expiration of TRADJENTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRADJENTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRADJENTA:-

You can seek FDA approval to launch a generic drug before the expiration of TRIJARDY XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIJARDY XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIJARDY XR:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ:-

You can seek FDA approval to launch a generic drug before the expiration of XELJANZ XR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XELJANZ XR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XELJANZ XR:-

You can seek FDA approval to launch a generic drug before the expiration of XTAMPZA ER's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XTAMPZA ER's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XTAMPZA ER:-

You can seek FDA approval to launch a generic drug before the expiration of XYWAV's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the XYWAV's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on XYWAV:-

You can seek FDA approval to launch a generic drug before the expiration of YOSPRALA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the YOSPRALA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on YOSPRALA:-